Immix Biopharma, Inc.

IMMX Nasdaq SEC CIK 1873835
Follow Immix Biopharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$13.9M −83.6% vs same quarter last year
EPS, diluted −$0.19 +20.8% vs same quarter last year
Operating cash flow −$12.3M −108.4% vs same quarter last year
Operating income −$15.9M −108.1% vs same quarter last year
Net income by quarter
−$4.8M
−$4.5M
−$6.6M
−$7.6M
−$10.6M
−$10.1M
−$11.6M
−$13.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$29.4M
FY24−$21.6M
FY23−$15.4M
FY22−$8.2M
FY21−$24.4M
FY20−$1.1M
FY19-
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$24.7M
FY24−$15.8M
FY23−$11.4M
FY22-
FY21−$1.6M
FY20-
FY19-